Drug Approval | August 28, 2021
Japan approves AstraZeneca’s Forxiga for chronic kidney disease
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
Board declares interim dividend of Rs 2 per equity share
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
The company has reported total income of Rs.826.40 crores for FY 2020-21
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
While overall survival data remain immature, the results pointed to a favourable trend.
Subscribe To Our Newsletter & Stay Updated
